Lyra Therapeutics LYRA 深 沪
已收盘 08-01 16:00:00 美东时间
6.58
-0.120
-1.79%
华盛通- 最 高7.06
- 今 开6.59
- 成交量 2.42万股
- 最 低 6.32
- 昨 收 6.70
- 总市值 1051.75万
- 52周最高 37.50
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 4.10
- 委 比 95.12%
- 总股本 159.84万
- 历史最高 1100.00
- 量 比 0.78
- 振 幅 11.04%
- 历史最低 4.10
- 每 手 1
- 风险率 2.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lyra Therapeutics registers shares for resale from warrant exercises
Lyra Therapeutics (NASDAQ:LYRA) registers 846,744 shares of common stock for resale by selling securityholders. Shares are issuable upon exercise of outstanding warrants; company will receive proceeds...
07-23 05:46
Lyra Therapeutics Secures $4.3M in Direct Offering
Lyra Therapeutics ( ($LYRA) ) just unveiled an update. On June 26, 2025, Lyra T...
06-27 22:59
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Lyra Therapeutics announced a registered direct offering of 423,372 common shares priced at $11.81 each, along with a concurrent private placement of warrants for up to 846,744 shares with an exercise price of $11.56. The initial gross proceeds are $5.0 million, with the potential for an additional $9.8 million from warrant exercises. Proceeds will be used for working capital, clinical development, and pre-commercialization of LYR-210. The offeri...
06-27 12:00
Primaris REIT to acquire Lime Ridge Mall for $416M
Primaris REIT (PMZ.UN:CA) will acquire 100% interest in Lime Ridge Mall in Hamilton, Ontario from Cadillac Fairview for $416M. The purchase will be funded with $235M in cash, $81M in REIT Units at $21...
06-17 04:30
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
HC Wainwright & Co. Maintains Neutral on Lyra Therapeutics, Raises Price Target to $16
HC Wainwright & Co. analyst Matthew Caufield maintains Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and raises the price target from $2 to $16.
06-10 19:12
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling over 30...
06-02 22:16
Market-Moving News for June 2nd
LYRA: 319% | Lyra Therapeutics' ENLIGHTEN 2 Phase 3 Trial Of LYR-210 For Chronic Rhinosinusitis Met Its Primary Endpoint, With LYR-210 Demonstrating Statistically Significant Improvement Compared To Sham Control In
06-02 19:43
Lyra Therapeutics' ENLIGHTEN 2 Phase 3 Trial Of LYR-210 For Chronic Rhinosinusitis Met Its Primary Endpoint, With LYR-210 Demonstrating Statistically Significant Improvement Compared To Sham Control In A Composite Of The Three Cardinal Symptoms
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078).ENLIGHTEN 2 trial also showed
06-02 19:05
